USFDA probe won’t affect supply: Lupin

NEW DELHI: Lupin, which has come under the glare of the USFDA, said on Friday that the inspection does not affect the supply of products from its Mandideep facility to other parts of the world.
The USFDA listed 15 ������observations'', which the company needs to address as part of a routine inspection of the company's Mandideep facility. "The outcome of this inspection does not affect the supply of products manufactured at this facility (Mandideep) across the world, or the approvability of pending applications with the USFDA," the company said in a filing to the BSE.